BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Explore the NASDAQ:LNTH financials. Find the Lantheus Holdings Inc financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...

Visit a quote page and your recently viewed tickers will be displayed here.

5:04p Inflation, tariffs put the brakes on this gun maker’s sales 4:51p Medicare may actually be in worse trouble than Social Security, according to the trustees ...